Parish WJ, Mark TL, Zarkin GA, et al. - A cross-sectional observational study was performed to evaluate differences in the quality of opioid use disorder (OUD) treatment received by Medicare beneficiaries enrolled in health plans that used prior authorization (PA) for buprenorphine-naloxone compared with those enrolled in plans that did not use PA. Between March 2012 and July 2017, researchers included a total of 71,294 beneficiaries with an OUD who filled at least one prescription for buprenorphine-naloxone. The results showed that in comparison with patients not subject to prior authorization, US Medicare patients subject to prior authorization for buprenorphine-naloxone are not more likely to receive high-quality treatment for opioid use disorder.